Brief: Ultragenyx Pharmaceutical Inc Says 2025 Revenue Guidance $640 Mln-$670 Mln
12/01/2025 16:04
Jan 12 (Reuters) - Ultragenyx Pharmaceutical Inc
RARE.O :
* ULTRAGENYX PHARMACEUTICAL INC - 2025 REVENUE GUIDANCE
$640M-$670M
* ULTRAGENYX PHARMACEUTICAL INC - PRELIMINARY 2024 TOTAL
REVENUE
OF $555 MILLION TO $560 MILLION, EXCEEDING TOP END OF GUIDANCE
Source text: ID:nGNX3rSf1M
Further company coverage: RARE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx